ATR
AptarGroup, Inc.
ATR has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ATR overall, supported by stronger modeled upside and stronger fundamentals.
ATR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Healthy |
ATR's balance sheet is currently healthy, and its revenue, profitability and cash flow are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $142 | — |
| Cheap | 24x | $100 | -29% |
| Fair | 32x | $131 | -7.7% |
| Current | 34x | $142 | — |
| Expensive | 35x | $145 | +2.1% |
Historical ranges are pointers, not guarantees.
ATR's PE is in its expensive range at 34x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ATR in the historical PE scenario, which offers more potential upside but is not a forecast.
ATR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ATR, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ATR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.08 | +48% |
| Q3 2026 | $4.12 | -34% |
| Q2 2026 | $5.53 | -4.7% |
| Q1 2026 | $5.84 | +6.8% |
| Q4 2025 | $5.89 | +6.5% |
| Q3 2025 | $6.24 | +25% |
| Q2 2025 | $5.80 | +22% |
| Q1 2025 | $5.47 | +17% |
| Q4 2024 | $5.53 | +30% |
ATR has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ATR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +6% |
| Q2 2026 | $1B | +6.3% |
| Q1 2026 | $982.9M | +11% |
| Q4 2025 | $962.7M | +14% |
| Q3 2025 | $961.1M | +5.7% |
| Q2 2025 | $966M | +6.1% |
| Q1 2025 | $887.3M | -3.1% |
| Q4 2024 | $848.1M | +1.1% |
ATR's revenue has grown year over year for six quarters in a row: $1B last quarter, up 6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1 points |
| Q2 2026 | 12% | -2.6 points |
| Q1 2026 | 11% | -1.8 points |
| Q4 2025 | 11% | -3.1 points |
| Q3 2025 | 14% | -1 points |
| Q2 2025 | 15% | +1.1 points |
| Q1 2025 | 13% | +0.5 points |
| Q4 2024 | 14% | +4.1 points |
ATR has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ATR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ATR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $98.6M | -14% |
| Q2 2026 | $45.9M | -27% |
| Q1 2026 | $53.3M | +106% |
| Q4 2025 | $96.9M | -14% |
| Q3 2025 | $114.3M | -30% |
| Q2 2025 | $62.5M | -17% |
| Q1 2025 | $25.9M | +55% |
| Q4 2024 | $112.2M | -19% |
ATR's free cash flow has been positive every quarter for seven years: $295M over the past year, down 6.4% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ATR on cash flow, with more consistent year-over-year improvement.
ATR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -61K shares |
| 1 year | -3.7% | -2.5M shares |
| 3 years | -4.3% | -2.9M shares |
| 5 years | -5.4% | -3.7M shares |
| Available history | -3.1% | -2M shares |
ATR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $30M |
| Q2 2026 | $50M |
| Q1 2026 | $100M |
| Q4 2025 | $175M |
| Q3 2025 | $40M |
| Q2 2025 | $70M |
| Q1 2025 | $80M |
| Q4 2024 | $37.3M |
ATR spent $355M buying back its own shares over the past year, up 56% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ATR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.5x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
ATR's net debt is about 1.5 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ATR on leverage, with a lower net debt burden relative to earnings.
ATR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 78.5 | Neutral |
ATR's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ATR PE vs Healthcare Sector
| Metric | ATR | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 33% above |
| PE % | 80 | 29 | 51 pts above |
ATR is trading at 34x earnings, a 33% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ATR on valuation relative to its sector.
ATR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $129.6 | 9.4% above |
| 20 week MA | $130.0 | 9% above |
| 50 week MA | $127.1 | 11% above |
| 100 week MA | $135.9 | 4.3% above |
| 200 week MA | $135.3 | 4.8% above |
ATR is in an uptrend: it's above all five of its weekly moving averages, and 4.8% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ATR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.0 | $135.7 | +18% |
| 2021 | $135.7 | $116.3 | -14% |
| 2022 | $116.3 | $110.0 | -5.4% |
| 2023 | $110.0 | $123.6 | +12% |
| 2024 | $123.6 | $158.2 | +28% |
| 2025 | $158.2 | $123.3 | -22% |
| 2026 YTD | $123.3 | $141.7 | +15% |
ATR has finished lower in three of the last six years. It's up 15% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ATR on returns for 2026, with the stronger performance.